ALSPW Spineway SAS

Revenue growth as of September 2023 by 40%

Revenue growth as of September 2023 by 40%

Press release        Ecully, October 13, 2023 – 6 p.m.



9-month revenue up 40% at €7.5 million

In thousands of euros



Unaudited data
20232022% change
Q1 revenue2,3991,342+79%
Q2 revenue3,0341,770+71%
Q3 revenue2,0772,249-8%
9M revenue*7,5095,361+40%

* 9M 2022 revenue included the share of revenue derived from Spine Innovations following its consolidation on July 21, 2022, i.e. €0.9 million.

Spineway recorded revenue of €2.1 million in the third quarter of 2023, taking the 9-month total to €7.5 million, a 40% increase compared with 2022. Revenue growth over the first 9 months was driven mainly by sales by Spine Innovations, consolidated in July 2022.

As announced, third-quarter revenue was automatically impacted by a less favorable impact from change in scope.

Sales in Asia amounted to €1.2 million over 9 months (up 34% on the same period in 2022). However, the third quarter saw a slowdown due to temporary problems with the Australian distributor of prosthetic discs and more stringent regulations, particularly in China and Vietnam. Specific sales and marketing initiatives have been implemented for Asia (approval of new products, targeted training initiatives), which should support sales in this area.

Sales continued to grow in Latin America, reaching €2.3 million over the first 9 months (up 8% on the same period in 2022). The region benefited from the first Spine Innovations sales in Mexico and the development of the Mont Blanc range in Chile.

Sales in Europe remained solid, increasing by 101% to €3.6 million in the period to end-September. The region was driven by strong momentum in France (growth of 67% to €2.1 million).

On the strength of a solid business base, Spineway confirms its aim of becoming an innovative player in France and internationally, leader in less invasive spine treatments.

Next event:

November 10, 2023: Extraordinary General Meeting

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.

Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).

ISIN: FR001400BVK2 - ALSPW        

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060




Eligible PEA / PME





ALSPW





Euronext Growth





AELIUM



Finance & Communication



Investor relations



Solène Kennis



Attachment



EN
13/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch